title: [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
abstract: OBJECTIVE
  Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non-clear-cell kidney cancer. In this retrospective multicenter study, we assessed tumor characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC).
  
  
  METHODS
  We evaluated 2,804 patients who had undergone renal surgery for pRCC or ccRCC between 1990 and 2006. The mean follow-up was 65 months.
  
  
  RESULTS
  Both pRCC and ccRCC groups were comparable concerning age, tumor grade and the incidence of regional lymph node metastasis at diagnosis. The percentage of male patients was higher in pRCC than in ccRCC (76.0% vs. 63.6%), pRCC patients suffered less often from advanced tumors (22.3% vs. 38.1%), visceral metastasis at diagnosis (8.1% vs. 14.5%) and died less frequently due to RCC progression (16.3% vs. 29.6%). Applying multivariable analyses pRCC was found to be an independent predictor of a favorable clinical course for patients with organ-confined RCC. In contrast in advanced disease papillary histology was significantly associated with a poor prognosis and early tumour-related death.
  
  
  CONCLUSIONS
  pRCC seem to be stratified into two different prognostic groups. Localized pRCC has a significantly better prognosis than ccRCC. In contrast, advanced pRCC is characterized by a worse clinical outcome. Whether these two different pRCC cohorts are consistent with the recently defined types 1 and 2 pRCC subtypes or are characterized by other typical genetic alterations, which would lead to a novel pRCC subclassification is currently under investigation within the German Renal Cancer Network.
authors.affiliation: Klinik für Urologie und urologische Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Waalkes
authors.forename: F C
authors.initials: FC
authors.lastname: Roos
authors.forename: H
authors.initials: H
authors.lastname: Eggers
authors.forename: S
authors.initials: S
authors.lastname: Schumacher
authors.forename: M
authors.initials: M
authors.lastname: Janssen
authors.forename: G
authors.initials: G
authors.lastname: Wegener
authors.forename: J W
authors.initials: JW
authors.lastname: Thüroff
authors.forename: R
authors.initials: R
authors.lastname: Hofmann
authors.forename: M
authors.initials: M
authors.lastname: Schrader
authors.forename: M A
authors.initials: MA
authors.lastname: Kuczyk
authors.forename: A J
authors.initials: AJ
authors.lastname: Schrader
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D018450:Disease Progression; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D055815:Young Adult